Co-Authors
This is a "connection" page, showing publications co-authored by STEVEN HSESHENG LIN and TING XU.
Connection Strength
1.077
-
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes. Blood Adv. 2024 10 08; 8(19):5215-5224.
Score: 0.246
-
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 04; 193:110121.
Score: 0.235
-
Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2022 11; 176:149-156.
Score: 0.214
-
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100391.
Score: 0.212
-
Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014 Dec; 113(3):379-84.
Score: 0.124
-
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277.
Score: 0.047